25 hasil untuk "Simone I. Strasser"

Is hepatic venous pressure gradient assessment required before liver resection in patients with cirrhosis and hepatocellular carcinoma?

Mauricio F. Silva; Simone I. Strasser; Flair J. Carrilho

Clinics, Vol. 68 No. 4 · Inggris · DOAJ Scopus

Is hepatic venous pressure gradient assessment required before liver resection in patients with cirrhosis and hepatocellular carcinoma?

Mauricio F. Silva; Simone I. Strasser; Flair J. Carrilho

Clinics, Vol. 68 No. 4 · 2013 · Inggris · DOAJ Scopus

Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma

Roslyn Vongsuvanh; David van der Poorten; Tristan Iseli dkk.

PLOS ONE, Vol. 11 No. 5 · 2016 · Inggris · PLOS Scopus

Robust biomarkers for population-level hepatocellular carcinoma (HCC) surveillance are lacking. We compared serum midkine (MDK), dickkopf-1 (DKK1), osteopontin (OPN) and AFP for HCC diagnosis in 86 HCC patients matched to 86 cirrhotics, 86 with chronic liver disease (CLD) and 86 healthy controls…

Juga tersedia di: DOAJ

The Inaugural Australian Centre for Hepatitis Virology Public Panel Discussion on Viral Hepatitis Research—Lessons in Scientific Community Outreach

Thomas Tu; Chaturaka Rodrigo; Simone I Strasser dkk.

Viruses, Vol. 13 No. 9 · 2021 · Inggris · DOAJ Scopus

Viral hepatitis remains one of the most significant health issues globally, directly responsible for over 1 million deaths each year and affecting almost 300 million people around the world. Scientific research in recent decades has brought about improvements in the lives of people living with…

National Survey of Real‐World Australian Treatment Patterns for Patients With Very‐Early‐To Intermediate‐Stage Hepatocellular Carcinoma

Stuart K. Roberts; Ammar Majeed; Kiran Rasaratnam dkk.

Cancer Medicine, Vol. 14 No. 5 · 2025 · Inggris · DOAJ Scopus

ABSTRACT Background/Purpose of the Study The treatment landscape for very early to intermediate stage hepatocellular carcinoma (HCC) is rapidly evolving, with new data and treatments emerging in recent years. There is a lack of data on current patterns of management for very early to intermediate…

Vessels that encapsulate tumour clusters vascular pattern in hepatocellular carcinomaKey points

Ken Liu; Claude Dennis; David S. Prince dkk.

JHEP Reports, Vol. 5 No. 8 · 2023 · Inggris · DOAJ Scopus

Summary: Vessels that encapsulate tumour clusters (VETC) is a distinct histologic vascular pattern associated with a novel mechanism of metastasis. First described in human cancers in 2004, its prevalence and prognostic significance in hepatocellular carcinoma (HCC) has only been appreciated in the…

Fever and Pancytopenia in a Liver Transplant Recipient: Going Against the Rules of Occam's Razor

Lionel Hon Wai Lum, MBBS; Fei Wen Chen, MBBS(Hons); Louise Jackett, FRCPA dkk.

Transplantation Direct, Vol. 3 No. 7 · 2017 · Inggris · DOAJ Scopus

Abstract. The syndrome of fever and pancytopenia is not infrequently encountered postliver transplant, and a broad differential list of infectious and noninfectious aetiologies can be invoked. A transplant patient is susceptible to more than 1 opportunistic infection or disease process. We…

Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis

Antonia Lepida; Massimo Colombo; Inmaculada Fernandez dkk.

PLOS ONE, Vol. 10 No. 9 · 2015 · Inggris · PLOS Scopus

Background: Liver stiffness determined by transient elastography is correlated with hepatic fibrosis stage and has high accuracy for detecting severe fibrosis and cirrhosis in chronic hepatitis C patients. We evaluated the clinical value of baseline FibroScan values for the prediction of safety and…

Juga tersedia di: DOAJ

Association between vessels that encapsulate tumour clusters vascular pattern and hepatocellular carcinoma recurrence following liver transplantation

Claude Dennis; David S. Prince; Leila Moayed-Alaei dkk.

Frontiers in Oncology, Vol. 12 · 2022 · Inggris · DOAJ Scopus

BackgroundVessels that encapsulate tumor clusters (VETC) is a novel vascular pattern seen on hepatocellular carcinoma (HCC) histology which has been shown to independently predict tumor recurrence and survival after liver resection. Its prognostic value in HCC patients receiving liver…

Real-world Data on the Diagnosis, Treatment and Management of Hepatocellular Carcinoma in the Asia-Pacific: The INSIGHT study

Yu Ki Sim; Ming Chuen Chong; Mihir Gandhi dkk.

Liver Cancer, Pp 1-1 (2023) · 2023 · Inggris · DOAJ Scopus

Introduction: Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide. While there has been rapid evolution in the treatment paradigm of HCC across the past decade, the extent to which these newly approved therapies are…

Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Harry Crane; Guy D. Eslick; Cameron Gofton dkk.

Clinical and Molecular Hepatology, Vol. 30 No. 3 · 2024 · Inggris · DOAJ Scopus

Background/Aims The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis plus defined markers of metabolic dysfunction…

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Zobair M. Younossi; Maria Stepanova; Mazen Noureddin dkk.

Hepatology Communications, Vol. 5 No. 7 · 2021 · Inggris · DOAJ Scopus

Patient‐reported outcomes (PROs) are important endpoints for clinical trials. The impact of investigational drugs on PROs of patients with advanced nonalcoholic steatohepatitis (NASH) was investigated. Patients with NASH with bridging fibrosis or compensated cirrhosis were enrolled in a phase 2…

P62 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis

Massimo Puoti; Graham Foster; Stanley Wang dkk.

Journal of Virus Eradication, Vol. 3 · 2017 · Inggris · DOAJ Scopus

MELD-GRAIL and MELD-GRAIL-Na Are Not Superior to MELD or MELD-Na in Predicting Liver Transplant Waiting List Mortality at a Single-center Level

John D. Chetwood, MBBS(Dist), DTM&H; Mark V. Wells, BSc; Tatiana Tsoutsman, PhD dkk.

Transplantation Direct, Vol. 8 No. 7 · 2022 · Inggris · DOAJ Scopus

Background. Controversy exists regarding the best predictive model of liver transplant waiting list (WL) mortality. Models for end-stage liver disease–glomerular filtration rate assessment in liver disease (MELD-GRAIL) and MELD-GRAIL-Na were recently described to provide better prognostication…

Implementing palliative care in hepatocellular carcinoma ambulatory clinics—study protocol for Accelerated translational research in PRImary liver CAncer (APRICA) randomised controlled palliative care trial

Cameron Gofton; Anna Di Bartolomeo; Rose Boutros dkk.

Trials, Vol. 25 No. 1 · 2024 · Inggris · DOAJ Scopus

Abstract Background Integration of symptom and palliative care for people with advanced cancer is established in many tumour types, but its role in people with hepatocellular carcinoma (HCC) has not been clearly defined. This study aims to evaluate the clinical and cost effectiveness of an…

Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up

Paul J. Clark; Patricia C. Valery; James Ward dkk.

BMC Gastroenterology, Vol. 22 No. 1 · 2022 · Inggris · DOAJ Scopus

Abstract Background First Nations Peoples of Australia are disproportionally affected by hepatitis C (HCV) infection. Through a prospective study we evaluated the outcome of direct-acting antiviral (DAA) therapy among First Nations Peoples with HCV infection. Methods Adults who initiated DAA…

The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45–75 years old with risk factors for chronic liver disease

Leon A. Adams; Deborah de Guingand; Gary P. Jeffrey dkk.

Trials, Vol. 26 No. 1 · 2025 · Inggris · DOAJ Scopus

Abstract Background Hepatocellular carcinoma (HCC) incidence and mortality rates are increasing at a greater pace than any other cancer in Australia. Cirrhosis is the major risk factor for HCC, and early detection of HCC through surveillance of people with cirrhosis can improve outcomes. However…

Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study

Haiyan Ma; Tien Huey Lim; Apinya Leerapun dkk.

JHEP Reports, Vol. 3 No. 6 · 2021 · Inggris · DOAJ Scopus

Background & Aims: Functional cure of chronic HBV infection (CHB) without life-long treatment requires the restoration of defective HBV-specific humoral and cellular immunity. Therapeutic vaccines based on the major structural and non-structural proteins have been tested in patients with CHB but…